The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic
© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVES: Data regarding bone marrow (BM) sampling and cytogenetic testing rates for identification of translocation (11q13;14q32) and their changes over time in a multiple myeloma (MM) population are limited. We analyzed these metrics at a clinic specializing in the treatment of MM.
METHODS: A total of 760 BM aspirate samples from 351 patients were collected between August 2004 and October 2021. We analyzed BM sampling statistics, cytogenetic testing frequency, and the incidence rates for the t(11;14) translocation in a single clinic specializing in the treatment of MM.
RESULTS: We report that most (54.4%) patients had only 1 aspirate collected; the main reason (64.6%) for BM collection was to confirm disease progression. Less than half (47.5%) of BM samples collected for evaluation of MM disease had cytogenetic testing, but the rates have markedly increased in recent years. Our data demonstrated an incidence rate of 19.3% for t(11;14).
CONCLUSIONS: This report suggests that some patients may need to retest for this genetic aberration due to the possibility of false negatives and the potential benefit of identifying the t(11;14) marker for patients who may be candidates for a highly effective targeted therapy consisting of the BCL-2 inhibitor venetoclax.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:161 |
|---|---|
| Enthalten in: |
American journal of clinical pathology - 161(2024), 1 vom: 04. Jan., Seite 16-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jew, Scott [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bone marrow aspirate |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 05.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajcp/aqad103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361095597 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361095597 | ||
| 003 | DE-627 | ||
| 005 | 20240108142046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajcp/aqad103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM361095597 | ||
| 035 | |a (NLM)37611113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jew, Scott |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a OBJECTIVES: Data regarding bone marrow (BM) sampling and cytogenetic testing rates for identification of translocation (11q13;14q32) and their changes over time in a multiple myeloma (MM) population are limited. We analyzed these metrics at a clinic specializing in the treatment of MM | ||
| 520 | |a METHODS: A total of 760 BM aspirate samples from 351 patients were collected between August 2004 and October 2021. We analyzed BM sampling statistics, cytogenetic testing frequency, and the incidence rates for the t(11;14) translocation in a single clinic specializing in the treatment of MM | ||
| 520 | |a RESULTS: We report that most (54.4%) patients had only 1 aspirate collected; the main reason (64.6%) for BM collection was to confirm disease progression. Less than half (47.5%) of BM samples collected for evaluation of MM disease had cytogenetic testing, but the rates have markedly increased in recent years. Our data demonstrated an incidence rate of 19.3% for t(11;14) | ||
| 520 | |a CONCLUSIONS: This report suggests that some patients may need to retest for this genetic aberration due to the possibility of false negatives and the potential benefit of identifying the t(11;14) marker for patients who may be candidates for a highly effective targeted therapy consisting of the BCL-2 inhibitor venetoclax | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bone marrow aspirate | |
| 650 | 4 | |a cytogenetic testing | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a t(11, 14) | |
| 700 | 1 | |a Goldwater, Marissa-Skye |e verfasserin |4 aut | |
| 700 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Regidor, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Emamy-Sadr, Marsiye |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Regina |e verfasserin |4 aut | |
| 700 | 1 | |a Eades, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical pathology |d 1945 |g 161(2024), 1 vom: 04. Jan., Seite 16-23 |w (DE-627)NLM000037001 |x 1943-7722 |7 nnns |
| 773 | 1 | 8 | |g volume:161 |g year:2024 |g number:1 |g day:04 |g month:01 |g pages:16-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajcp/aqad103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 161 |j 2024 |e 1 |b 04 |c 01 |h 16-23 | ||